Featured Author Podcast: Danavorexton Promotes Respiration and Wakefulness
Moderator: James P. Rathmell, M.D.
Participants: Rebecca L. Wu, M.D. and Max B. Kelz, M.D., Ph.D.
Articles Discussed:
TAK-925 (danavorexton), an Orexin Receptor 2 Agonist, Reduces Opioid-Induced Respiratory Depression and Sedation Without Affecting Analgesia in Healthy Adult Males
Alluring Potential to Accelerate Emergence and Ameliorate Opioid-induced Respiratory Depression without Antagonizing Analgesia: Danavorexton Enters the Anesthetic Landscape
Transcript
